Keyphrases
Monoclonal Antibody
100%
Broadly Neutralizing
100%
Henipavirus
100%
Broadly Neutralizing Antibodies
63%
Immunogen
36%
F Protein
18%
Virus
18%
G Protein
18%
Focused Approach
9%
Immunogenicity
9%
Bona Fide
9%
Severe Respiratory Failure
9%
Hendra
9%
Prophylactic Treatment
9%
Conserved Epitopes
9%
Protective Efficacy
9%
Vaccine Antibodies
9%
Pathogenic Agents
9%
Highly Pathogenic
9%
Patient Samples
9%
Infectious Agents
9%
Structure Function
9%
Human Immunoglobulin
9%
Severe Neurological Disease
9%
Biosafety Level 4
9%
Future Vaccines
9%
BNAbs
9%
Monoclonal Antibody Cocktail
9%
Vaccine Development
9%
Therapeutic Agents
9%
Receptor Binding
9%
Immediate Needs
9%
Antiviral Countermeasure
9%
2-design
9%
Case Fatality Rate
9%
Rationally Designed
9%
Highly Pathogenic Virus
9%
Cedar Virus
9%
Ghana Virus
9%
Human mAb
9%
Nipah
9%
Convalescent Patients
9%
Effective Therapy
9%
Public Health Risk
9%
Mice Transgenic
9%
Glycoprotein
9%
Pharmacology, Toxicology and Pharmaceutical Science
Human Monoclonal Antibody
100%
Henipavirus
100%
Neutralizing Antibody
63%
Guanine Nucleotide Binding Protein
18%
Infectious Agent
18%
Monoclonal Antibody
18%
Human Immunoglobulin
9%
Epitope
9%
Case Fatality Rate
9%
Transgenic Mouse
9%
Respiratory Tract Disease
9%
Antivirus Agent
9%
Vaccine Development
9%
Immunogenicity
9%
Neurologic Disease
9%
Glycoprotein
9%
Receptor
9%
Synapsin II
9%
Immunology and Microbiology
Henipavirus
100%
Human Monoclonal Antibody
100%
Neutralizing Antibody
63%
Virus
45%
Infectious Agent
18%
Monoclonal Antibody
18%
Immunogenicity
9%
Cladistics
9%
Transgenic Mouse
9%
Epitope
9%
Glycoprotein
9%
Receptor Binding
9%
Case Fatality Rate
9%
Human Immunoglobulin
9%